Cargando…

Postoperative clinical outcomes with and without short-term intravenous tranexamic acid after posterior lumbar interbody fusion: A prospective cohort study

The use of tranexamic acid (TXA) in posterior lumbar interbody fusion (PLIF) surgery is believed to be beneficial for reducing intraoperative blood loss, postoperative drainage volume (PDV), and length of hospital stay (LOS). However, whether continued administration of intravenous TXA within 24 hou...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Xianqun, Wang, Xiaochen, Shi, Liang, Tian, Fangtao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10659680/
https://www.ncbi.nlm.nih.gov/pubmed/37986288
http://dx.doi.org/10.1097/MD.0000000000035911
_version_ 1785148364110692352
author Ji, Xianqun
Wang, Xiaochen
Shi, Liang
Tian, Fangtao
author_facet Ji, Xianqun
Wang, Xiaochen
Shi, Liang
Tian, Fangtao
author_sort Ji, Xianqun
collection PubMed
description The use of tranexamic acid (TXA) in posterior lumbar interbody fusion (PLIF) surgery is believed to be beneficial for reducing intraoperative blood loss, postoperative drainage volume (PDV), and length of hospital stay (LOS). However, whether continued administration of intravenous TXA within 24 hours after surgery is more beneficial to patients has not yet been studied. This study prospectively analyzed the perioperative outcomes of patients who received and did not receive intravenous TXA within 24 hours after PLIF (≥2 segments) surgery from January 2018 to December 2021. A total of 78 and 69 patients were included in the TXA (receive intravenous TXA intraoperatively and within 24 hours postoperatively) and non-TXA (only receive intravenous TXA intraoperatively) groups, respectively. No significant differences were observed in the intraoperative blood loss and operative time between the 2 groups. The postoperative drainage volume, postoperative drainage time, and length of hospital stay in the TXA group were significantly lower than those in the non-TXA group. The rates and volumes of postoperative blood and albumin transfusions were significantly lower in the TXA group than those in the non-TXA group. No significant differences were observed in the perioperative complication rates between the 2 groups. No increase in thrombosis-related complications was observed with postoperative TXA administration. Short-term TXA use after PLIF (≥2 segments) surgery is safe. In addition to intraoperative use of TXA, additionally administration of intravenous TXA within 24 hours postoperatively can improve the perioperative clinical outcomes of patients without increasing the risk of thrombotic events.
format Online
Article
Text
id pubmed-10659680
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-106596802023-11-17 Postoperative clinical outcomes with and without short-term intravenous tranexamic acid after posterior lumbar interbody fusion: A prospective cohort study Ji, Xianqun Wang, Xiaochen Shi, Liang Tian, Fangtao Medicine (Baltimore) 7100 The use of tranexamic acid (TXA) in posterior lumbar interbody fusion (PLIF) surgery is believed to be beneficial for reducing intraoperative blood loss, postoperative drainage volume (PDV), and length of hospital stay (LOS). However, whether continued administration of intravenous TXA within 24 hours after surgery is more beneficial to patients has not yet been studied. This study prospectively analyzed the perioperative outcomes of patients who received and did not receive intravenous TXA within 24 hours after PLIF (≥2 segments) surgery from January 2018 to December 2021. A total of 78 and 69 patients were included in the TXA (receive intravenous TXA intraoperatively and within 24 hours postoperatively) and non-TXA (only receive intravenous TXA intraoperatively) groups, respectively. No significant differences were observed in the intraoperative blood loss and operative time between the 2 groups. The postoperative drainage volume, postoperative drainage time, and length of hospital stay in the TXA group were significantly lower than those in the non-TXA group. The rates and volumes of postoperative blood and albumin transfusions were significantly lower in the TXA group than those in the non-TXA group. No significant differences were observed in the perioperative complication rates between the 2 groups. No increase in thrombosis-related complications was observed with postoperative TXA administration. Short-term TXA use after PLIF (≥2 segments) surgery is safe. In addition to intraoperative use of TXA, additionally administration of intravenous TXA within 24 hours postoperatively can improve the perioperative clinical outcomes of patients without increasing the risk of thrombotic events. Lippincott Williams & Wilkins 2023-11-17 /pmc/articles/PMC10659680/ /pubmed/37986288 http://dx.doi.org/10.1097/MD.0000000000035911 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 7100
Ji, Xianqun
Wang, Xiaochen
Shi, Liang
Tian, Fangtao
Postoperative clinical outcomes with and without short-term intravenous tranexamic acid after posterior lumbar interbody fusion: A prospective cohort study
title Postoperative clinical outcomes with and without short-term intravenous tranexamic acid after posterior lumbar interbody fusion: A prospective cohort study
title_full Postoperative clinical outcomes with and without short-term intravenous tranexamic acid after posterior lumbar interbody fusion: A prospective cohort study
title_fullStr Postoperative clinical outcomes with and without short-term intravenous tranexamic acid after posterior lumbar interbody fusion: A prospective cohort study
title_full_unstemmed Postoperative clinical outcomes with and without short-term intravenous tranexamic acid after posterior lumbar interbody fusion: A prospective cohort study
title_short Postoperative clinical outcomes with and without short-term intravenous tranexamic acid after posterior lumbar interbody fusion: A prospective cohort study
title_sort postoperative clinical outcomes with and without short-term intravenous tranexamic acid after posterior lumbar interbody fusion: a prospective cohort study
topic 7100
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10659680/
https://www.ncbi.nlm.nih.gov/pubmed/37986288
http://dx.doi.org/10.1097/MD.0000000000035911
work_keys_str_mv AT jixianqun postoperativeclinicaloutcomeswithandwithoutshorttermintravenoustranexamicacidafterposteriorlumbarinterbodyfusionaprospectivecohortstudy
AT wangxiaochen postoperativeclinicaloutcomeswithandwithoutshorttermintravenoustranexamicacidafterposteriorlumbarinterbodyfusionaprospectivecohortstudy
AT shiliang postoperativeclinicaloutcomeswithandwithoutshorttermintravenoustranexamicacidafterposteriorlumbarinterbodyfusionaprospectivecohortstudy
AT tianfangtao postoperativeclinicaloutcomeswithandwithoutshorttermintravenoustranexamicacidafterposteriorlumbarinterbodyfusionaprospectivecohortstudy